One other advancement towards the treatment of SCD is the replacement of the mutated β-globin gene through CRISPR-Cas9 knock-in in a planned phase 1/2 trial in subjects ≥12 years old to 35 years old with SCD, via a single infusion of sickle allele-modified CD34+ HSPCs (CRISPR_SCD001). The gene discussed is CD34; the disease is Schnyder corneal dystrophy.